Walker E M, Fazekas-May M A, Bowen W R
University of Arkansas for Medical Sciences, Little Rock.
Clin Lab Med. 1990 Jun;10(2):323-54.
It is well established that many drugs, such as the aminoglycoside antibiotics and the chemotherapeutic drug cisplatin, are capable of inducing both nephrotoxicity and ototoxicity. The factors that selectively predispose the kidney and inner ear to the toxic effects of these agents as well as the mechanism by which damage is produced are not well defined. The two organs differ greatly in their exposure to these toxic agents. The kidney has an abundant vascular supply and tends to selectively concentrate a number of drugs within the renal cortex or medulla, often to toxic levels. The vascular supply of the inner ear is not as extensive. In addition, the stria vascularis of the cochlea may act as a functional regulator of drug entry into inner ear fluids. The absorption of drugs into perilymph and endolymph is poorly understood. Selective accumulation theories of drug accumulation in the inner ear must be questioned because of the results of recent pharmacokinetic studies, which give contrary data. Drug-induced ototoxicity and nephrotoxicity can be explained on a cellular level. Studies using radiolabeled gentamicin suggest that binding mechanisms of the drug to the plasma membrane of the outer hair cells of the cochlea and vestibular apparatus and to the brush border receptors of the renal proximal convoluted tubules are similar. This suggests the same receptor sites for aminoglycosides occur in otic and renal organs. Calcium channels are implicated because of the reversibility of aminoglycoside-induced changes in the cochlear microphonic by calcium and other divalent cations. Calcium channel blockers, such as verapamil, reduce the nephrotoxicity of a number of drugs that are also ototoxic. Studies are needed to assess potential prevention of ototoxicity by use of these same calcium channel blocking agents. Aminoglycosides concentrate within the lysosomes of renal proximal tubular cells. Possibly, they also may concentrate in lysosomes within the cells of cochlear and vestibular structures. Nephrotoxic heavy metals concentrate within proximal tubular cells and, some, such as lead or bismuth, specifically concentrate within intracytoplasmic or intranuclear inclusion bodies. Studies are necessary to determine if the same metals accumulate within the cochlear and vestibular cells, inclusion bodies, or both. These questions and others must be answered before it can be determined why many nephrotoxic drugs and agents are also ototoxic.
众所周知,许多药物,如氨基糖苷类抗生素和化疗药物顺铂,能够引发肾毒性和耳毒性。选择性地使肾脏和内耳易受这些药物毒性影响的因素以及损伤产生的机制尚未明确。这两个器官在接触这些有毒药物方面差异很大。肾脏有丰富的血管供应,往往会选择性地将多种药物集中在肾皮质或髓质内,常常达到中毒水平。内耳的血管供应没那么广泛。此外,耳蜗的血管纹可能作为药物进入内耳液的功能调节器。药物进入外淋巴和内淋巴的吸收情况了解甚少。由于近期药代动力学研究结果给出了相反的数据,内耳药物蓄积的选择性蓄积理论必须受到质疑。药物诱导的耳毒性和肾毒性可以在细胞水平上得到解释。使用放射性标记庆大霉素的研究表明,该药物与耳蜗和前庭装置外毛细胞的质膜以及肾近端曲管的刷状缘受体的结合机制相似。这表明氨基糖苷类药物在耳和肾器官中存在相同的受体位点。由于钙和其他二价阳离子可逆转氨基糖苷类药物引起的耳蜗微音器电位变化,因此钙通道与之有关。钙通道阻滞剂,如维拉帕米,可降低许多具有耳毒性药物的肾毒性。需要开展研究以评估使用这些相同的钙通道阻滞剂预防耳毒性的可能性。氨基糖苷类药物集中在肾近端小管细胞的溶酶体内。它们也可能集中在耳蜗和前庭结构细胞内的溶酶体中。具有肾毒性的重金属集中在近端小管细胞内,有些,如铅或铋,特别集中在胞质内或核内包涵体内。有必要开展研究以确定相同的金属是否在耳蜗和前庭细胞、包涵体内或两者中蓄积。在确定为何许多具有肾毒性的药物和制剂也具有耳毒性之前,必须回答这些问题及其他问题。